Acta Med. 2014, 57: 49-55

https://doi.org/10.14712/18059694.2014.39

RADIOIODINE TREATMENT OF GRAVES’ DISEASE – DOSE/RESPONSE ANALYSIS

Jitka Čepkováa, Jiří Horáčeka, Jaroslav Vižďab, Jiří Doležalb

a4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic
bDepartment of Nuclear Medicine, University Hospital Hradec Králové, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic

References

1. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012; 379(9821): 1155–66. <https://doi.org/10.1016/S0140-6736(11)60782-4>
2. Abraham P, Acharya S. Current and emerging treatment options for Graves’ hyperthyroidism. Ther Clin Risk Manag 2010; 6: 29–40.
3. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364(6): 542–50. <https://doi.org/10.1056/NEJMct1007101>
4. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1991; 1(2): 129–35. <https://doi.org/10.1089/thy.1991.1.129>
5. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012; 97(12): 4549–58. <https://doi.org/10.1210/jc.2012-2802>
6. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2004; 61(5): 641–8. <https://doi.org/10.1111/j.1365-2265.2004.02152.x>
7. Sridama V, Mccormick M, Kaplan EL, Fauchet R, Degroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. N Engl J Med 1984; 311(7): 426–32. <https://doi.org/10.1056/NEJM198408163110702>
8. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21(6): 593–646.
9. Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf) 2007; 66(6): 757–64. <https://doi.org/10.1111/j.1365-2265.2007.02841.x>
10. Lewis A, Atkinson B, Bell P, et al. Outcome of 131I therapy in hyperthyroidism using a 550 MBq fixed dose regimen. Ulster Med J 2013; 82(2): 85–8.
11. Gupta SK, Mcgrath S, Rogers K, et al. Fixed dose (555 MBq; 15 mCi) radioiodine for the treatment of hyperthyroidism: outcome and its predictors. Intern Med J 2010; 40(12): 854–7. <https://doi.org/10.1111/j.1445-5994.2010.02348.x>
12. Watson AB, Brownlie BE, Frampton CM, Turner JG, Rogers TG. Outcome following standardized 185 MBq dose 131I therapy for Graves’ disease. Clin Endocrinol (Oxf) 1988; 28(5): 487–96. <https://doi.org/10.1111/j.1365-2265.1988.tb03683.x>
13. Farrar JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol (Oxf) 1991; 35(3): 207–12. <https://doi.org/10.1111/j.1365-2265.1991.tb03523.x>
14. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves’ disease: a clinical outcome study. Eur J Nucl Med 2001; 28(10): 1489–95. <https://doi.org/10.1007/s002590100621>
15. Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 1995; 43(3): 325–9. <https://doi.org/10.1111/j.1365-2265.1995.tb02039.x>
16. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25(3): 186–93. <https://doi.org/10.1111/j.1365-2362.1995.tb01547.x>
17. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab 2003; 88(3): 978–83. <https://doi.org/10.1210/jc.2002-020805>
18. Turner J, Sadler W, Brownlie B, Rogers T. Radioiodine therapy for Graves’ disease: multivariate analysis of pretreatment parameters and early outcome. Eur J Nucl Med 1985; 11(6–7): 191–3. <https://doi.org/10.1007/BF00279066>
19. Kahaly GJ, Bartalena L, Hegedus L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 2011; 21(6): 585–91. <https://doi.org/10.1089/thy.2011.2106.ed3>
20. Sztal-Mazer S, Nakatani VY, Bortolini LG, Boguszewski CL, Graf H, De Carvalho GA. Evidence for higher success rates and successful treatment earlier in Graves’ disease with higher radioactive iodine doses. Thyroid 2012; 22(10): 991–5. <https://doi.org/10.1089/thy.2011.0362>
21. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86(8): 3611–7.
22. Kalinyak JE, Mcdougall IR. How should the dose of iodine-131 be determined in the treatment of Graves’ hyperthyroidism? J Clin Endocrinol Metab 2003; 88(3): 975–7. <https://doi.org/10.1210/jc.2002-021801>
23. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83(2): 685–7. <https://doi.org/10.1210/jcem.83.2.4538>
24. Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volume in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 1996; 81(9): 3257–60.
25. Boelaert K, Syed AA, Manji N, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf) 2009; 70(1): 129–38. <https://doi.org/10.1111/j.1365-2265.2008.03291.x>
26. Erem C, Kandemir N, Hacihasanoglu A, Ersoz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine 2004; 25(1): 55–60. <https://doi.org/10.1385/ENDO:25:1:55>
27. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001; 86(8): 3488–93.
28. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 2000; 85(3): 1038–42.
29. Sabri O, Zimny M, Schulz G, et al. Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84(4): 1229–33.
30. Collier A, Ghosh S, Hair M, Malik I, Mcgarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. Hormones (Athens) 2009; 8(4): 273–8. <https://doi.org/10.14310/horm.2002.1243>
31. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007; 334(7592): 514. <https://doi.org/10.1136/bmj.39114.670150.BE> <PubMed>
32. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid 2004; 14(7): 525–30. <https://doi.org/10.1089/1050725041517093>
33. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004; 89(9): 4439–44. <https://doi.org/10.1210/jc.2004-0247>
34. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid 2002; 12(2): 135–9. <https://doi.org/10.1089/105072502753522365>
35. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330(24): 1731–8.
36. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2002; 87(3): 1073–7.
37. Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998; 83(1): 40–6.
38. Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab 1999; 84(2): 499–503.
39. Grosso M, Traino A, Boni G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm 2005; 20(2): 218–23. <https://doi.org/10.1089/cbr.2005.20.218>
40. Horacek J, Franklyn JA. Radioiodine treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab 2003; 88(12): 6113. <https://doi.org/10.1210/jc.2003-031172>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive